Register for our free email digests:
Jessica Merrill

Latest From Jessica Merrill
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
Exelixis Has Renewed Momentum Heading Into 2021
The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.
Teva's Slow Recovery Proceeds With Flat Revenue Forecast In 2021
The company's specialty franchises are on track for solid growth but the North American generics outlook remains lackluster.